Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Think that this will move into the teens soon and hold that position.
I like the vision over £35-45 etc but to me that is really quite a bit jump and don't feel we are in that space or category just yet. More than happy to be proven wrong but feels over ambitious/ tad unrealistic.
10,000 share buy
"
It will jump up to £20 on the next contract. We all know it's coming, UK, FR, DE, could be anywhere
"
Jump to £20 may not happen but a jump to £15 easily achievable. Testing is needed for foreseeable future and if Biden wins in US, he will call for more testing and with NCYT's gold standard test kit, the orders from US will start to flow in. Once the order news lands from US and other countries, this will go bonkers. Now if GH can throw a RNS next week then it is blue skies....
good volume again Today ,many sellers cleared ,and somee nice sized share buys ,
are the larger buyers loading up with more shares
how high will this share price finish Today
from yesterday
takeover article (twitter)
Https://mobile.twitter.com/iMuesliBrown/status/1321818360812896258
It will jump up to £20 on the next contract. We all know it's coming, UK, FR, DE, could be anywhere, but it's imminent.
There is no argument with those comparisons and market valuations based on smiler but no where near advanced or profitable companies porky !
The question is what is needed for the re -rate we deserve ?
As for timescale we just have to be patient ?
I have spent the last couple of days looking at all Diagnostics related stocks listed in addition to all the information we have that is proven in an attempt to value this stock.
I think we can all agree that due to the amazing success and rapid growth so far of this business the market has been unable to properly put a valuation on NCYT. The only broker note we have is the one from Numis giving £13.65 as fair value and £35 as Blue Sky and this is already out of date.
So, this is my conservative calculation: -
I mentioned last week that SourceBio was listing on the AIM. Now this is a Diagnostics Testing business nowhere near the quality and level of NCYT, not even in the same league but what we do know is that it was properly valued we assume, its shares were oversubscribed and it came to the market on a market cap of £ 130m.
That business has confirmed revenue of £20 million and an EBITDA of £ 3 million so we can roughly say that the market valuation for this Diagnostics testing business is valued at over 6X Revenue or 43X EBITDA.
Meanwhile over at Omega Diagnostics it has confirmed revenues of circa £10 million and was loss making in the last year but also has a market cap of £ 135m so in this case the valuation is even higher.
NCYT on the other hand delivered £73 million in the first half and an EBITDA of £ 49 million and expected its second half to be stronger than the first half. So even if we use a pessimistic view and say that NCYT only does the same in the second half, yet in reality we already know its secured countless worldwide orders, then applying £ 150m Revenue and £ 100m EBITDA using the same valuation metrics as the above two the market cap should be over £4 bn or in our case north of £45 a share.
Now if someone wants to tell me where I am going wrong here, I am all ears, but this rough calculation does not consider any of the current wins or product lines, winterplex etc etc. If I use the £500m+ sales estimate that we think it will be, the valuation gets even higher!!!
For me I’m just going to ignore the day to day swings of this SP and let it do what it does because if this company isn’t seriously valued at a significantly higher level than where we are today for a blue chip like NCYT there is something seriously wrong with the market.
Good Luck all